Patents by Inventor Takashi SHIRAKURA

Takashi SHIRAKURA has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190374515
    Abstract: The present invention pertains to a therapeutic drug or prophylactic drug for diabetic nephropathy, said drug comprising a compound represented by formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient.
    Type: Application
    Filed: November 27, 2017
    Publication date: December 12, 2019
    Applicant: TEIJIN PHARMA LIMITED
    Inventors: Takashi SHIRAKURA, Shunsuke TSUJIMOTO, Yoshiki TSUBOSAKA
  • Patent number: 10301300
    Abstract: Provided are a xanthine oxidase inhibitor, a drug for improving vascular endothelial function, and an excellent therapeutic or prophylactic drug for diseases associated with xanthine oxidase such as gout, hyperuricaemia, and for diseases associated with vascular endothelial functional disorder containing a compound represented in a formula (I) or the pharmaceutically acceptable salt thereof as an active ingredient.
    Type: Grant
    Filed: May 1, 2018
    Date of Patent: May 28, 2019
    Assignee: TEIJIN LIMITED
    Inventors: Takashi Shirakura, Yoshimasa Takahashi, Asahi Kawana, Chikashi Kanazawa
  • Publication number: 20180244665
    Abstract: Provided are a xanthine oxidase inhibitor, a drug for improving vascular endothelial function, and an excellent therapeutic or prophylactic drug for diseases associated with xanthine oxidase such as gout, hyperuricaemia, and for diseases associated with vascular endothelial functional disorder containing a compound represented in a formula (I) or the pharmaceutically acceptable salt thereof as an active ingredient.
    Type: Application
    Filed: May 1, 2018
    Publication date: August 30, 2018
    Applicant: Teijin Pharma Limited
    Inventors: Takashi SHIRAKURA, Yoshimasa TAKAHASHI, Asahi KAWANA, Chikashi KANAZAWA
  • Publication number: 20170217948
    Abstract: Provided are a xanthine oxidase inhibitor, a drug for improving vascular endothelial function, and an excellent therapeutic or prophylactic drug for diseases associated with xanthine oxidase such as gout, hyperuricaemia, and for diseases associated with vascular endothelial functional disorder containing a compound represented in a formula (I) or the pharmaceutically acceptable salt thereof as an active ingredient.
    Type: Application
    Filed: July 29, 2015
    Publication date: August 3, 2017
    Applicant: Teijin Pharma Limited
    Inventors: Takashi SHIRAKURA, Yoshimasa TAKAHASHI, Asahi KAWANA, Chikashi KANAZAWA
  • Patent number: 9545445
    Abstract: The present invention relates to a therapeutic drug or a preventive drug for hypertension or high-normal blood pressure, comprising (a) and (b) as active ingredients: (a) a 2-phenylthiazole compound represented by formula (I) or a pharmaceutically acceptable salt thereof; (b) at least one compound or a pharmaceutically acceptable salt thereof selected from the group consisting of calcium antagonists, renin-angiotensin system inhibitors, diuretics, sympatholytic agents, vasodilators, and medicinally acceptable salts of these. The present invention also relates to a therapeutic method or a preventive method for hypertension or high-normal blood pressure, comprising administering the above (a) and (b) in amounts effective for treating or preventing hypertension or high-normal blood pressure.
    Type: Grant
    Filed: June 25, 2010
    Date of Patent: January 17, 2017
    Assignee: Teijin Pharma Limited
    Inventors: Takashi Shirakura, Mizuho Tamura, Yoshimasa Takahashi, Ippei Kuwahara
  • Patent number: 9388174
    Abstract: The present invention provides: a compound represented by formula (I) or a pharmaceutically acceptable salt thereof, which has an excellent inhibitory activity on xanthine oxidase and is useful as a therapeutic agent or a prophylactic agent for diseases associated with xanthine oxidase, such as gout, hyperuricemia, tumor lysis syndrome, urinary tract stone, hypertension, dyslipidemia, diabetes, cardiovascular diseases including arteriosclerosis and heart failure, renal diseases including diabetic nephropathy, respiratory diseases including chronic obstructive pulmonary disease, inflammatory bowel disease or autoimmune diseases; and a medicine or a pharmaceutical composition comprising the compound or the salt as an active ingredient.
    Type: Grant
    Filed: January 30, 2014
    Date of Patent: July 12, 2016
    Assignee: Teijin Pharma Limited
    Inventors: Asahi Kawana, Chikashi Kanazawa, Yoshimasa Takahashi, Takashi Shirakura
  • Publication number: 20150376174
    Abstract: The present invention provides: a compound represented by formula (I) or a pharmaceutically acceptable salt thereof, which has an excellent inhibitory activity on xanthine oxidase and is useful as a therapeutic agent or a prophylactic agent for diseases associated with xanthine oxidase, such as gout, hyperuricemia, tumor lysis syndrome, urinary tract stone, hypertension, dyslipidemia, diabetes, cardiovascular diseases including arteriosclerosis and heart failure, renal diseases including diabetic nephropathy, respiratory diseases including chronic obstructive pulmonary disease, inflammatory bowel disease or autoimmune diseases; and a medicine or a pharmaceutical composition comprising the compound or the salt as an active ingredient.
    Type: Application
    Filed: January 30, 2014
    Publication date: December 31, 2015
    Applicant: TEIJIN PHARMA LIMITED
    Inventors: Asahi KAWANA, Chikashi KANAZAWA, Yoshimasa TAKAHASHI, Takashi SHIRAKURA
  • Publication number: 20150005506
    Abstract: The purpose of the present invention is to provide a novel therapeutic agent or a novel prophylactic agent for diseases associated with abnormal glucose metabolism. The present invention is a therapeutic agent or a prophylactic agent for diseases associated with abnormal glucose metabolism, which comprises a 2-phenylthiazole compound represented by formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient.
    Type: Application
    Filed: January 25, 2013
    Publication date: January 1, 2015
    Applicants: NATIONAL UNIVERSITY CORPORATION TOTTORI UNIVERSITY, TEIJIN PHARMA LIMITED
    Inventors: Ichiro Hisatome, Shunsuke Tsujimoto, Takashi Shirakura, Shinya Hiramitsu
  • Publication number: 20130109726
    Abstract: The present invention provides a therapeutic or preventive agent for hypertension or normal high blood pressure, and for renal dysfunction, that is more effective than existing drugs. More specifically, the present invention provides a sustained-release pharmaceutical composition for treating or preventing hypertension or normal high blood pressure, and for renal dysfunction, comprising as an active ingredient a 2-phenylthiazole compound represented by the following formula (I) or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: June 24, 2011
    Publication date: May 2, 2013
    Applicant: TEIJIN PHARMA LIMITED
    Inventors: Takashi Shirakura, Mizuho Tamura, Yoshimasa Takahashi, Ippei Kuwahara
  • Publication number: 20110046192
    Abstract: The present invention relates to a therapeutic drug or a preventive drug for hypertension or high-normal blood pressure, comprising (a) and (b) as active ingredients: (a) a 2-phenylthiazole compound represented by formula (I) or a pharmaceutically acceptable salt thereof; (b) at least one compound or a pharmaceutically acceptable salt thereof selected from the group consisting of calcium antagonists, renin-angiotensin system inhibitors, diuretics, sympatholytic agents, vasodilators, and medicinally acceptable salts of these. The present invention also relates to a therapeutic method or a preventive method for hypertension or high-normal blood pressure, comprising administering the above (a) and (b) in amounts effective for treating or preventing hypertension or high-normal blood pressure.
    Type: Application
    Filed: June 25, 2010
    Publication date: February 24, 2011
    Applicant: Teijin Pharma Limited
    Inventors: Takashi SHIRAKURA, Mizuho Tamura, Yoshimasa Takahashi, Ippei Kuwahara